Annexon outlines 2024 priorities with late-stage clinical milestones across upstream complement portfolio for autoimmune, ophthalmic and neurodegenerative diseases

Anx005 phase 3 pivotal data in guillain-barrÉ syndrome (gbs) on track for first half of 2024;potential to be first approved treatment for gbs patients in the u.s.

ANNX Ratings Summary

ANNX Quant Ranking